Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells

Oncotarget(2023)10.18632/oncotarget.28517Source: DataRank Database

Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells is a research paper published in Oncotarget (2023). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.82)OA: goldTopics (43)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Gary D. Luker ORCID,Seema Agarwal ORCID,Hossein Tavana ORCID,Astha Lamichhane ORCID

Live enrichment

PubMed:37791907 OpenAlex:https://openalex.org/W4387326673

National Institutes of Health

Grant: 5R33CA225549-02

A High Throughput Human Tumor Modeling Technology for Cancer Drug Discovery

National Institutes of Health

Grant: 3R15CA216413-01A1S1

Modeling Treatment-Induced Drug Resistance of Colon Cancer Cells and Treatment Strategies

NCI NIH HHS

Grant: R15 CA216413

NCI NIH HHS

Grant: R33 CA225549

FWCI

0.82

Citation Percentile

0.7%

Citation Trend

2024

2025

2026

goldLicense: cc-by

journalhttps://www.oncotarget.com/article/28517/pdf/

publisherhttps://www.oncotarget.com/article/28517/pdf/

publisherhttps://www.oncotarget.com/lookup/doi/10.18632/oncotarget.28517

journalhttps://doi.org/10.18632/oncotarget.28517

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37791907

Fields of Study

Cancer Cells and MetastasisFOXO transcription factor regulationMicrotubule and mitosis dynamics03 medical and health sciences0302 clinical medicineHumansProto-Oncogene Proteins B-rafPhosphatidylinositol 3-KinasesColorectal NeoplasmsErbB ReceptorsMitogen-Activated Protein Kinase Kinases

MeSH Terms

HumansColorectal NeoplasmsPhosphatidylinositol 3-KinasesMitogen-Activated Protein Kinase KinasesProto-Oncogene Proteins B-rafErbB Receptors

Keywords

Cancer stem cellColorectal cancerCancer researchCancerMedicineLGR5Cancer cellPI3K/AKT/mTOR pathwayMAPK/ERK pathwayDrug resistanceProtein kinase BMEK inhibitorSignal transductionInternal medicineBiologyCell biologyProto-Oncogene Proteins B-rafErbB ReceptorsMitogen-Activated Protein Kinase KinasesPhosphatidylinositol 3-KinasesHumansColorectal NeoplasmsResearch Papercancer stem cellscombination treatmentpatient-derived tumor model

Sustainable Development Goals

SDG 0: Good health and well-being